Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Suppression of Nasopharyngeal and Gastric Tumors Growth in a Mouse Model by Antibodies to Epstein-Barr Virus LMP-1 Protein

Abdelhalim Khenchouche
,
Mounir M. Salem-Bekhit
* ,
Ahd Ahmed Mansour
ORCID logo ,
Mohammad N. Alomary
* ORCID logo ,
Xiaohui Wang
,
Hayat Ali Alzahrani
,
Ibrahim M. Al Hosiny
,
Ehab I. Taha
ORCID logo ,
Gamal A. Shazly
,
Yacine Benguerba
* ORCID logo ,
Karim Houali
ORCID logo
Version 1 : Received: 31 May 2023 / Approved: 31 May 2023 / Online: 31 May 2023 (14:42:00 CEST)

A peer-reviewed article of this Preprint also exists.

Khenchouche, A.; Salem-Bekhit, M.M.; Mansour, A.A.; Alomary, M.N.; Wang, X.; Alzahrani, H.A.; Hosiny, I.M.A.; Taha, E.I.; Shazly, G.A.; Benguerba, Y.; Houali, K. Suppression of Nasopharyngeal and Gastric Tumor Growth in a Mouse Model by Antibodies to Epstein–Barr Virus LMP1 Protein. Microorganisms 2023, 11, 1712. Khenchouche, A.; Salem-Bekhit, M.M.; Mansour, A.A.; Alomary, M.N.; Wang, X.; Alzahrani, H.A.; Hosiny, I.M.A.; Taha, E.I.; Shazly, G.A.; Benguerba, Y.; Houali, K. Suppression of Nasopharyngeal and Gastric Tumor Growth in a Mouse Model by Antibodies to Epstein–Barr Virus LMP1 Protein. Microorganisms 2023, 11, 1712.

Abstract

Abstract: The study aimed to investigate the antitumor efficacy of anti-LMP1 antibodies in EBV-positive nasopharyngeal and stomach cell lines and xenograft models. The study also exam-ined the NF-κB expression and cell cycle activation of NPC serum exosome-associated LMP1. An-ti-LMP1 antibody treatment before or during cell implantation prevented tumor growth in nude mice. A small dose of antibodies resulted in complete tumor regression for at least three months af-ter the tumors had grown in size. The consumption of antigen-antibody complexes by tumor cells limited tumor growth. In vitro experiments showed that anti-LMP1 antibodies killed EBV-positive NPC- or GC-derived epithelial cell lines and EBV-positive human B cell lines but not EBV-negative cell lines. Treatment with anti-LMP1 reduced NF-κB expression in cells. The animal model experi-ments showed anti-LMP1 inhibited and prevented NPC- or GC-derived tumor growth. The results suggest that LMP1 antibody immunotherapy could cure nasopharyngeal cancer, EBV-positive gastric carcinoma, and EBV-associated lymphomas. However, further validation of these findings is required through human clinical trials.

Keywords

EBV oncogenes; LMP1; Nasopharyngeal; gastric carcinomas; mouse model; tumor suppression and prevention

Subject

Medicine and Pharmacology, Epidemiology and Infectious Diseases

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.